I attended the AGM and 24 hours on reflection IMHO the exciting message is the Valve in Valve story. It’s a $3.4b annual area and our DurAVAR is on data evidence the leading candidate to tackle the problem. Why replace a faulty valve with the same faulty valve. Go for our product with the best data. We are in pole position for the FDA to give us the nod for this requirement. $3.4b is a massive figure.
Ann: AGM Chairman Address and CEO Presentation, page-21
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |